

Docket No. 13760-7030

22. (New) The method of claim 17, wherein the polypeptide has the sequence depicted in SEQ ID NO: 2.

*AK
Cones*

23. (New) A method of inhibiting apoptosis in a human, comprising administering an effective amount of a polypeptide having a sequence that is substantially equivalent to SEQ ID NO: 2 to said human. --

REMARKS

In response to the restriction requirement dated June 4, 2002, Applicants elect Group I, claims 1-13 and 17-23 for initial pursuit on the merits, without traverse. In response to the species requirement, Applicants elect stroke as the specific neurological disorder for initial pursuit. The claims readable thereon include claims 1-7, 12, 13, 17-23, and it is further asserted that these claims are generic with regards to the species election.

The claim amendments have been made in order to correct various antecedency, typographical and Markush group issues, and find support in the specification and claims as filed, as do the new claims. New claims 21 and 22 find support at least in claims 1 and 17 as filed. New claim 23 finds support at least in Figures 5-7, Examples 5-9, and in the abstract. No new matter is added.

If the Examiner has any questions concerning this Response, the Examiner is respectfully requested to telephone Applicant's agent at the following telephone number 650-849-4908

DATE: November 4, 2002

Respectfully submitted,

By: David W. Maher
David W. Maher, Reg. No. 40,077

BINGHAM MCCUTCHEN LLP
Three Embarcadero Center, Suite 1800
San Francisco, California 94111-4067
Telephone: (650) 849-4400

Docket No. 13760-7030

ATTACHMENT A

Version with markings to show changes made

What is claimed is:

1. (Amended) A method of treating a neurological disorder in a human patient which comprises administering to said human patient an effective amount of a ~~composition comprising a~~ polypeptide comprising a sequence substantially equivalent to SEQ ID NO: 2.
2. (Amended) The method of claim 1 wherein the polypeptide is administered in a composition further comprises comprising a pharmaceutically acceptable carrier.
3. (Amended) The method of claim 1 wherein the ~~composition~~ polypeptide is administered orally, transdermally, intravenously, intrasynovially, intramuscularly, intraocularly, intranasally, intrathecally, or topically.
4. (Amended) The method of claim 1 wherein ~~administering the composition~~ polypeptide is administered ~~is in~~ conjunction with another method of treating said neurological disorder.
5. The method of claim 1, wherein the neurological disorder is caused by oxidative stress response in neuronal tissue.
6. The method of claim 1, wherein the neurological disorder is caused by the activation of a neuron specific, stress-activated protein kinase.
7. The method of claim 6, wherein the protein kinase is c-Jun amino-terminal kinase 3.
8. (Amended) The method of claim 1 wherein the neurological disorder is a disorder selected from dementia, dementia of the Alzheimer's type, bipolar disorders, mood disorder with depressive features, mood disorder with major depressive-like episode, mood disorder with manic features, mood disorder with mixed features, substance-induced mood disorder ~~and~~, mood disorder not otherwise specified (NOS), panic disorder without agoraphobia, panic disorder with agoraphobia, ~~agoraphobia~~ ~~agoraphobia~~ without history of panic disorder, social phobia, posttraumatic stress disorder, acute stress disorder, substance-induced anxiety disorder ~~and~~, anxiety disorder not otherwise specified (NOS), dyskinesias ~~and~~, behavioral manifestations of mental retardation, conduct disorder and autistic disorder.
9. (Amended) The method of claim 8, wherein the neurological disorder is a dementia ~~is selected from the group consisting of~~ vascular dementia, dementia due to HIV disease, dementia due to head trauma, dementia due to Parkinson's disease, dementia due to Huntington's disease, dementia due to Pick's disease, dementia due to Creutzfeldt-Jakob disease,

Docket No. 13760-7030

substance-induced persisting dementia, dementia due to multiple etiologies and dementia not otherwise specified (NOS).

10. (Amended) The method of claim 8, wherein said ~~dementia-neurological disorder~~ is dementia of the Alzheimer's type.

11. (Amended) The method of claim 10, wherein said dementia of the Alzheimer's type is selected from the group consisting of dementia of the Alzheimer's type with early onset uncomplicated, dementia of the Alzheimer's type with early onset with delusions, dementia of the Alzheimer's type with early onset with depressed mood, dementia of the Alzheimer's type with late onset uncomplicated, dementia of the Alzheimer's type with late onset with delusions and dementia of the Alzheimer's type with late onset with depressed mood.

12. (Amended) The method of claim 1, wherein the ~~composition~~-polypeptide is administered in a targeted drug delivery system.

13. The method of claim 12, wherein the targeted drug delivery system is a liposome coated with an antibody that specifically targets neuronal tissue.

17. (Amended) A method of treating a ~~neurological disease in a human subject for a neurological disease~~ selected from the group consisting of Alzheimer's disease, stroke, amyotrophic lateral sclerosis, age associated memory impairment and Parkinson's disease, the method comprising administering to said human an effective amount of a ~~composition comprising a polypeptide~~ having a sequence that is substantially equivalent to SEQ ID NO: 2.

18. (Amended) The method of claim 17 wherein the polypeptide is administered in a composition further comprises comprising a pharmaceutically acceptable carrier.

19. The method of claim 17 wherein the composition is administered orally, transdermally, intravenously, intrasynovially, intramuscularly, intraocularly, intranasally, intrathecally, or topically.

20. The method of claim 17 wherein the method is used in conjunction with another method of treating said neurological disorder.

-- 21. (New) The method of claim 1, wherein the polypeptide has the sequence depicted in SEQ ID NO: 2.

22. (New) The method of claim 17, wherein the polypeptide has the sequence depicted in SEQ ID NO: 2.

23. (New) A method of inhibiting apoptosis in a human, comprising administering an effective amount of a polypeptide having a sequence that is substantially equivalent to SEQ ID NO: 2 to said human. --